Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable…
<!-- Name:DistributionId Value:8780989 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
ANGPTL3
Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety
Higher than yet-tested doses of the novel ANGPTL3-targeting antisense agent vupanorsen modestly reduced non-HDL cholesterol and…